Dyax Corp., of Cambridge, Mass., reported net product sales of Kalbitor (ecallantide) of $3 million for the fourth quarter and $8.8 million for full-year 2010. Kalbitor, for treatment of acute attacks of hereditary angioedema in patients 16 and older, became commercially available in the first quarter of 2010. The company projected Kalbitor sales of $20 million to $24 million in 2011. For the quarter Dyax had a net loss of $8.9 million or 9 cents per share, compared to a net loss of $10.9 million or 14 cents per share for the same quarter in 2009. For the full year, the net loss was $24.5 million or 26 cents per share, compared to $62.4 million or 90 cents per share in 2009. The company ended 2010 with $77.4 million in cash.
Onyx Pharmaceuticals Inc., of Emeryville, Calif., reported that full-year net global sales of Nexavar grew 11 percent in 2010 to $934 million, and increased 9 percent in the fourth quarter to $257.4 million, compared to the same periods in 2009. Onyx and Bayer market and develop Nexavar (sorafenib) tablets, an anticancer therapy for the treatment of unresectable liver cancer and advanced kidney cancer, in more than 100 countries. Non-GAAP net income for the full year was down 27.9 percent to $39.2 million, or 63 cents per diluted share, compared to non-GAAP net income of $54.4 million, or 89 cents per diluted share, for the same period in 2009. For the fourth quarter, the non-GAAP net loss was $17.4 million, or 28 cents per diluted share, compared to $8.8 million and 14 cents per diluted share for the same period in 2009. The company ended 2010 with $577.9 million in cash.
ViroPharma Inc., of Exton, Pa., reported record full-year net product sales of $439 million up 41 percent over 2009 including $177 million in net sales (up 82 percent over 2009) of Cinryze (C1 esterase inhibitor [human]) for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema. Total net sales for the fourth quarter were $121.6 million, up 38 percent compared to the fourth quarter of 2009. Fourth quarter Cinryze net sales were $52.5 million, up 46 percent compared to the same quarter of 2009. The company said it expects Cinryze sales of $235 million to $260 million in 2011. Net sales of Vancocin, for Clostridium difficile infection, were $67.8 million for the quarter, up 31 percent, and $259.6 million for the full year, up 22 percent. Non-GAAP adjusted net income for the fourth quarter and full year was $45.6 million and $156.9 million, respectively, compared to $20.8 million and $83.6 million, respectively, for the same periods in 2009. The company ended 2010 with $505 million in cash.